To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Hypertension
Interventions
DRUG

KN060

The dose was calculated based on the fasting body weight of the subject D1, and the corresponding volume of KN060 was drawn and added to 0.9% sodium chloride injection to prepare a 100 ml solution by intravenous drip every two weeks

DRUG

0.9% Sodium Chloride Injection

0.9% sodium chloride 100ml was administered as placebo by intravenous drip every two weeks

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Suzhou Alphamab Co., Ltd.

INDUSTRY